Palvella Therapeutics (PVLA) Amortization of Deferred Charges (2020)

Palvella Therapeutics (PVLA) has reported Amortization of Deferred Charges for 3 consecutive years, with -$23000.0 the latest figure, recorded in Q2 2021.

• In Q2 2021, Amortization of Deferred Charges rose 46.51% year-over-year to -$23000.0; the TTM figure through Jun 2021 stood at -$388000.0 (down 211.17% YoY), while the FY2021 annual figure was -$91000.0, up 50.54% from the prior year.
• Amortization of Deferred Charges rose to -$23000.0 in Q2 2021 per PVLA's latest filing, from -$25000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $199000.0 in Q1 2020 and bottomed at -$259000.0 in Q3 2020.
• Historically, Amortization of Deferred Charges has averaged -$4875.0 across 3 years, with a median of -$24000.0 in 2021.
• Annual changes were most pronounced in 2020 — Amortization of Deferred Charges tumbled 359.0% — and 2021, when it soared 46.51%.
• Palvella Therapeutics' Amortization of Deferred Charges stood at $93000.0 in 2019, then plunged by 187.1% to -$81000.0 in 2020, then soared by 71.6% to -$23000.0 in 2021.
• Business Quant data shows PVLA's Amortization of Deferred Charges at -$23000.0 in Q2 2021, -$25000.0 in Q1 2021, and -$81000.0 in Q4 2020.